跳转至内容
Merck

1046205

USP

氨曲南

United States Pharmacopeia (USP) Reference Standard

别名:

[2S-[2α,3β(Z)]]-2-[[[1-(2-氨基-4-噻唑基)-2-[(2-甲基-4-氧代-1-磺基-3-氮杂环丁烷)氨基]-2-氧代亚乙基]氨基]氧代]-2-甲基丙酸

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C13H17N5O8S2
CAS号:
分子量:
435.43
MDL號碼:
分類程式碼代碼:
41116107
PubChem物質ID:
NACRES:
NA.24

等級

pharmaceutical primary standard

API 家族

aztreonam

製造商/商標名

USP

應用

pharmaceutical (small molecule)

格式

neat

儲存溫度

−20°C

SMILES 字串

C[C@H]1[C@H](NC(=O)\C(=N/OC(C)(C)C(O)=O)c2csc(N)n2)C(=O)N1S(O)(=O)=O

InChI

1S/C13H17N5O8S2/c1-5-7(10(20)18(5)28(23,24)25)16-9(19)8(6-4-27-12(14)15-6)17-26-13(2,3)11(21)22/h4-5,7H,1-3H3,(H2,14,15)(H,16,19)(H,21,22)(H,23,24,25)/b17-8-/t5-,7-/m0/s1

InChI 密鑰

WZPBZJONDBGPKJ-VEHQQRBSSA-N

正在寻找类似产品? 访问 产品对比指南

一般說明

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

應用

Aztreonam USP reference standard is meant to use for specified quality tests and assays.

Also used to prepare standard and system suitability solutions for assay according to the given below monographs of United States Pharmacopeia (USP):
  • Aztreonam
  • Aztreonam for Injection
  • Aztreonam Injection

分析報告

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

其他說明

Sales restrictions may apply.

儲存類別代碼

11 - Combustible Solids

水污染物質分類(WGK)

WGK 2

閃點(°F)

Not applicable

閃點(°C)

Not applicable


分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Aztreonam Injection
United States Pharmacopeia and National Formulary
United States Pharmacopeia, 39(3), 462-462 (2018)
Aztreonam for Injection
United States Pharmacopeia and National Formulary
United States Pharmacopeia, 39(3), 463-463 (2018)
Baroukh Maurice Assael
Expert review of anti-infective therapy, 9(11), 967-973 (2011-10-28)
An aerosol form of aztreonam lysinate has recently been developed as a treatment for cystic fibrosis patients suffering from chronic Pseudomonas aeruginosa lung colonization. Local administration means the drug can reach mucus concentrations in the order of hundreds of times
D H Johnson et al.
The Medical clinics of North America, 79(4), 733-743 (1995-07-01)
Aztreonam is a monocyclic beta-lactam antibiotic that is active exclusively against the aerobic gram-negative bacilli. It is not ototoxic or nephrotoxic and so is used as an alternative to aminoglycosides in a variety of clinical situations. In polymicrobial infections or
Kimberly A Pesaturo et al.
The Annals of pharmacotherapy, 46(7-8), 1076-1085 (2012-07-06)
To evaluate the pharmacology, clinical efficacy, and safety of aztreonam lysine for inhalation (AZLI) for cystic fibrosis (CF)-related signs and symptoms of pulmonary disease. Literature was searched in MEDLINE through PubMed and cross-referenced with EMBASE (1980-June 2012). The key search

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门